Spark Therapeutics (ONCE) Misses Q2 EPS by 35c

Spark Therapeutics (NASDAQ: ONCE) reported Q2 EPS of ($0.60), $0.35 worse than the analyst estimate of ($0.25). Revenue for the quarter came in at $1.29 million versus the consensus estimate of $4.5 million.

"During the past quarter we've made great strides in advancing our clinical programs and we are reaffirming our guidance to report top-line results from our pivotal Phase 3 trial of SPK-RPE65 before the end of the year," said Jeffrey D. Marrazzo, co-founder and chief executive officer of Spark. "We also expanded our preclinical pipeline with both the selection of a lead program in the area of neurodegenerative diseases and a lead product candidate in our hemophilia A program."

For earnings history and earnings-related data on Spark Therapeutics (ONCE) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c